EyePoint, Inc. (EYPT) Stock Analysis

Q: What is the EYPT stock price target?

Take-profit $32.34 (+148.0% upside). Prior stop was $12.15.

Q: Is EYPT overvalued or undervalued?

EyePoint, Inc. trades at a P/E of N/A (forward -4.6). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about EYPT?

18 analysts cover EYPT with a consensus score of 4.3/5. Average price target: $37.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

$13.00+148.0% A.UpsideScore 4.7/10#108 of 158 Biotechnology

Stop $12.15Target $32.34(analyst − 13%)A.R:R 14.8:1

Analyst target$37.17+185.9%12 analysts

$32.34our TP

$13.00price

$37.17mean

$68

Sell if holding. Engine safety override at $13.00: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 14.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 9.25; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.8 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-4.6

Mkt Cap$1.1B

EV/EBITDA-4.9

Profit Mgn0.0%

ROE-72.2%

Rev Growth161.7%

Beta1.91

DividendNone

Rating analysts18

Quality Signals

Piotroski F4/9

Options Flow

P/C9.25bearish

IV93%elevated

Max Pain$20+53.8% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality1.815%0.27

Growth10.015%1.50

Momentum1.610%0.16

Sentiment6.610%0.66

Insider Activity5.010%0.50

Peer Rank2.610%0.26

Technical Setup6.45%0.32

Risk Profile2.55%0.13

Catalyst2.55%0.13

Overall (Σ contributions)4.73

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Obv

1.0

Macd

1.4

Ma Position

2.2

Rsi

3.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+5.0%/30d) — pullback in uptrend, not confirmed weakness

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -473% of revenueNo competitive moatQuality concerns

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Short Interest

1.6

Beta

3.6

Max Pain Risk

7.0

Debt Equity

8.1

High short interest justified: 19%Elevated put/call: 9.25High IV: 93%

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.2

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 6 days

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.5

Value Rank

1.0

Growth Rank

9.0

Industry growth leader

GatesMomentum 1.6<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 14.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

35 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $12.53Resistance $15.33

Price Targets

$12

$32

A.Upside+148.8%

A.R:R14.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)

! Momentum score 1.6/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

1/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is EYPT stock a buy right now?

Sell if holding. Engine safety override at $13.00: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 14.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 9.25; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.15. Score 4.7/10, moderate confidence.

What is the EYPT stock price target?

Take-profit target: $32.34 (+148.0% upside). Prior stop was $12.15. Stop-loss: $12.15.

What are the risks of investing in EYPT?

Quality below floor (1.8 < 4.0).

Is EYPT overvalued or undervalued?

EyePoint, Inc. trades at a P/E of N/A (forward -4.6). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about EYPT?

18 analysts cover EYPT with a consensus score of 4.3/5. Average price target: $37.

What does EyePoint, Inc. do?EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious...

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.